Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00393055 · ClinicalTrials.gov registry record · Phase 3
Xylitol Adult Caries Trial (X-ACT)
A Phase 3 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 3
- Development phase
- 709
- Enrollment target
NCT00393055: Completed Phase 3 study, sponsored by University of North Carolina, Chapel Hill.
NCT00393055 is a Phase 3 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 709 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00393055, a Phase 3 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 709 participants
- Enrollment target
Study Summary
The purpose of the trial is to determine the extent to which daily use of xylitol lozenges reduces the appearance of new caries lesions in adults who tend to experience such lesions (i.e., caries-active adults).
Interventions
- DIETARY_SUPPLEMENT xylitol
- DIETARY_SUPPLEMENT inactive lozenge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 709 participants |
| Start Date | 2007-01 |
| Est. Completion | 2011-06 |
| Phase | Phase 3 |
What the finished NCT00393055 record still lists
NCT00393055 is an interventional study that assigns participants to a tested intervention. The registered 709 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which xylitol is the first listed.
NCT00393055 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00393055 about?
NCT00393055 is a clinical study titled "Xylitol Adult Caries Trial (X-ACT)". The purpose of the trial is to determine the extent to which daily use of xylitol lozenges reduces the appearance of new caries lesions in adults who tend to experience such lesions (i.e., caries-active adults).
What is the current status of trial NCT00393055?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 709 participants. The study started on 2007-01. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00393055?
The interventions under investigation include: xylitol (DIETARY_SUPPLEMENT), inactive lozenge (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00393055?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00393055's enrollment target sits among peer trials
709 505th of 2000 higher than 1,496 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06179160 · 710 participants · Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- NCT06235697 · 710 participants · Phase 3
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
- NCT06470867 · 710 participants · NA
Randomized Controlled Effectiveness Trial of VA S.A.V.E.
- NCT07022483 · 710 participants · Phase 3
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia